News and Trends 11 Sep 2019
Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy
The German pharmaceutical company Grünenthal has licensed a donor cell therapy for chronic low back pain from the Australian biotech Mesoblast in a deal that could be worth over €900M. Under the terms of the deal, Grünenthal will gain exclusive rights to commercialize Mesoblast’s cell therapy for chronic low back pain in Europe and Latin […]